sur Theranexus (EPA:ALTHX)
THX Pharma: Cash Position and Key Advances as of September 30, 2026
THX Pharma, a biopharmaceutical company specializing in rare neurological diseases, announced available cash of €16 million as of September 30, 2026, down from €17.5 million in the previous quarter. This decrease is due to preparations for the pivotal Phase 3 trial of Batten-1 and the repayment of bank loans, although the clinical development of Batten-1 is funded by Biocodex.
The quarter was also marked by two major developments: the filing of applications for authorization for the Batten-1 trial with several regulatory agencies and the granting of a patent protecting Batten-1 until 2041. THX Pharma also recorded revenue of 3.2 million euros in the first half of 2026, reducing its net loss to 0.1 million euros.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Theranexus